… , we aimed to describe the effectiveness and safety of afatinib, gefitinib, and erlotinib for …
a first-line treatment than gefitinib or erlotinib for elderly patients with EGFR-mutated advanced …

… elderly and non-elderly EGFR-mutated NSCLC patients by comparing the efficacy of diverse
first-line treatments with gefitinib, erlotinib… , for elderly and non-elderly patients harboring …

… Erlotinib demonstrated a better PFS compared with first-line standard chemotherapy in the
trials OPTIMAL [21] (13.1 months for erlotinib … the efficacy of osimertinib in 36 elderly patients …

… First-line gefitinib for patients with advanced non–small-cell … low-dose erlotinib would be safe
and effective in elderly or frail … -dose erlotinib was associated with efficacy and safety in frail …

… For example, most of the older patients and patients with poor PS included in the current
study were treated with gefitinib or erlotinib. In addition, the sample size was relatively small, …

… of non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations. Using a
cohort of unselected patients treated with erlotinib, we sought to further describe patient and …

… ramucirumab/bevacizumab combined with erlotinib could improve PFS compared with erlotinib
treatment alone as the first-line treatment in advanced patients with EGFR-mutant NSCLC…

… In conclusion, first-line erlotinib shows sufficient efficacy in older patients with EGFR-mutant
NSCLC, even when started at 100 mg/day. The results of the present study also suggest the …

… non-squamous NSCLC treated with erlotinib specifically after failure of first-line
pemetrexed-containing chemotherapy. We assessed the effectiveness, safety and tolerability of …

… effectiveness and safety profiles of EGFR-TKI rechallenge after first-line EGFR-TKI treatment
in elderly patients … dose change for erlotinib, and the dose reduction in the elderly of smaller …